Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of General Internal Medicine
Published in: Journal of General Internal Medicine 1/2008

01-01-2008 | Updates

Update in Women’s Health 2006–2007

Authors: Jennifer R. Zebrack, MD, Alda Maria Gonzaga, MD, MS, Joan M. Neuner, MD, MPH, Ann B. Nattinger, MD, MPH

Published in: Journal of General Internal Medicine | Issue 1/2008

Login to get access

Excerpt

In this paper, we summarize recent women’s health articles and guidelines that could potentially change practice, presented at the 30th annual meeting of the Society of General Internal Medicine. …
Literature
1.
Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321–33.PubMedCrossRef
2.
Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women’s Health Initiative randomized controlled trial. JAMA. 2004;291:1701–12.PubMedCrossRef
3.
Nelson HD. Commonly used types of postmenopausal estrogen for treatment of hot flashes: Scientific review. JAMA. 2004;291:1610–20.PubMedCrossRef
4.
Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: A randomised controlled trial. Lancet. 2000;356:2059–63.PubMedCrossRef
5.
Strearns V, Beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: A randomized controlled trial. JAMA. 2003;289:2827–34.CrossRef
6.
Stearns V, Johnson MD, Rae JM, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst. 2003;95:1758–64.PubMed
7.
Nedrow A, Miller J, Walker M, et al. Complementary and alternative therapies for the management of menopause-related symptoms: A systematic review. Arch Intern Med. 2006;166:1453–65.PubMedCrossRef
8.
Barlow WE, White E, Ballard-Barbash R, et al. Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst. 2006;98:1204–14.PubMedCrossRef
9.
Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371–88.PubMedCrossRef
10.
Lin JH, Russell G, Gertz B. Pharmacokinetics of alendronate: an overview. Int J Clin Pract. 1999;101(suppl):18–26.
11.
Bone HG, Hosking D, Devogelaer JP, et al. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350(12):1189–99.PubMedCrossRef
12.
Shane E, et al. Osteonecrosis of the jaw: More research needed. J Bone Miner Res. 2006;21(10):1503–05.PubMedCrossRef
13.
Stafford RS, Drieling RL, Hersh AL. National trends in osteoporosis visits and osteoporosis treatment, 1988–2003. Arch Intern Med. 2004;164(14):1525–30.PubMedCrossRef
14.
ACOG Committee Opinion No. 330. Evaluation and management of abnormal cervical cytology and histology in the adolescent. Obstet Gynecol. 2006;107:963–8
15.
Mosca L, Banka CL, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation. 2007;115:1481–501.PubMedCrossRef
16.
The American College of Obstetrics and Gynecology (ACOG) Practice Bulletin No 73. Contraception in women with coexisting medical conditions. Obstet Gynecol. 2006;107:1453–72.
17.
Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mort Wkly Rep Recomm Rep. 2007;56:1–24.
18.
Sexually Transmitted Diseases Treatment Guidelines, 2006. Morb Mort Wkly Rep Recomm Rep. 2006;55:1–94. (Erratum in MMWR Recomm Rep. 2006;55:997).
19.
The American College of Obstetrics and Gynecology (ACOG), Practice Bulletin No. 72. Vaginitis. Obstet Gynecol. 2006;107:1195–206.
Metadata
Title
Update in Women’s Health 2006–2007
Authors
Jennifer R. Zebrack, MD
Alda Maria Gonzaga, MD, MS
Joan M. Neuner, MD, MPH
Ann B. Nattinger, MD, MPH
Publication date
01-01-2008
Publisher
Springer-Verlag
Published in
Journal of General Internal Medicine / Issue 1/2008
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-007-0451-6

Other articles of this Issue 1/2008

Journal of General Internal Medicine 1/2008 Go to the issue

Editorial

Teaching Tips—A new series in JGIM

Original Article

Intimate Partner Violence Exposure and Change in Women’s Physical Symptoms Over Time

Case Reports/Clinical Vignettes

Prolonged Cerebellar Ataxia: An Unusual Complication of Hypoglycemia

Original Article

Overcoming Poor Attendance to First Scheduled Colonoscopy: A Randomized Trial of Peer Coach or Brochure Support

Perspectives

Evidence Does Not Support Clinical Screening of Literacy

Original Article

Factors Affecting Physicians’ Responses to Patients’ Requests for Antidepressants: Focus Group Study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits